Similarly, pharmacological inhibitors of AKR1B10 were capable of reducing steatosis, fibrosis, and inflammation in mouse with non-alcoholic steatohepatitis [26]. Here, AKR1B10 is linked to metabolic dysfunction-associated steatohepatitis.